I assume that you're only joking, but seriously I don't think MOGN invested that money for SUPG's stock to appreciate as much as they did to close the dacogen deal. Future Dacogen revenues will more than compensate them for any small loss in SUPG equity. As CVA had stated, it was merely window dressing to help demonstrate to shareholders that the stock was worth more than the $6 range. It says nothing, however, about what the stock price should be.
I agree with what your saying. A good biotech partnership for a late stage drug would go something like this, MOGN pays upfront fee of 50 million plus takes an equity stake for another 30 million. Milestones include 10 million for filing of NDA, plus another 50 million upon FDA approval and pays for all other clinical trials. The key being that SUPG would build a salesforce of say 40 reps and split Dacogen revenue 50/50. Maybe get 10 percent royalty on EU and ROW sales. Thats what SUPG shareholders wanted, they didn't get it and thats why smart money is moving on.